It is time to drop euphemisms like DNA medicines and gene-based medicines: gene therapy has made it through to the commercial mainstream.
More than 17 years after the first (supposedly) successful treatment was publicised, a big-ticket, big-pharma deal was signed for a gene therapy product last week, when Sanofi-Aventis agreed a €518 million licence for Oxford BioMedica plc’s TroVax,...
This page requires a Science|Business Network Membership
This page is available to Science|Business Network Members only. If you are already a member then please log in (above).
Note if you are only registered to receive our Bulletin, or have previously purchased an item from our store, this does not give you access to the full benefits of the site. Join Now and plug into the Science|Business Network to get full access to all our news, events and business opportunities.
Science|Business is the first independent media company that brings together researchers, investors and policy makers in the European innovation community. It does so with a top-quality team and unique network of Europe's leading scientific institutions, corporations, policy makers and IP and VC specialists.
Be where innovation begins – become a member. Click here to learn more.